- Docket No.
- 23-2194
- Appellate Court
- Fourth Circuit
Goal
- Reverse the district court's dismissal of the case
Issues
Case History
Litigation Content
Why this Matters:
The Plaintiff alleges that West Virginia’s abortion ban, which effectively bans the sale of mifepristone in the state, conflicts with the Food and Drug Administration’s (FDA’s) federal approval of the drug. Ensuring that individuals have access to FDA-approved medication abortions enables patients to receive necessary reproductive health care.
Potential Impact:
Overriding the FDA’s expertise and preventing individuals from accessing effective medication for abortion services will jeopardize their health and safety.
22 Major Filings
- Case Calendared for Oral Argument (Aug 30, 2024)
- Amicus Brief_Historians (Aug 6, 2024)
- Reply Brief by GenBioPro (May 20, 2024)
- Amicus Brief_Advancing American Freedom (Apr 15, 2024)
- Amicus Brief_American Center for Law and Justice (Apr 15, 2024)
- Amicus Brief_Family Research Council (Apr 15, 2024)
- Amicus Brief_Heartbeat International (Apr 15, 2024)
- Amicus Brief_Judicial Watch (Apr 15, 2024)
- Amicus Brief_Life Legal Defense Foundation (Apr 15, 2024)
- Amicus Brief_State of Arkansas et al (Apr 15, 2024)
- Amicus Brief_Institute for Faith and Family (Apr 11, 2024)
- Response Brief by Raynes (Apr 8, 2024)
- Amicus Brief_American College of Obstetricians and Gynecologists (Feb 16, 2024)
- Amicus Brief_City of Baltimore et al (Feb 14, 2024)
- Amicus Brief_Doctors for America (Feb 14, 2024)
- Amicus Brief_Economists (Feb 14, 2024)
- Amicus Brief_Food and Drug Law and Health Law Scholars (Feb 14, 2024)
- Amicus Brief_North Carolina (Feb 14, 2024)
- Brief by GenBioPro (Feb 7, 2024)
- Joint Appendix (Feb 7, 2024)
- Briefing Order (Nov 28, 2023)
- Docketing Notice (Nov 15, 2023)